Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
A melanocortin agonist related to melanotan II, but it is a defined cyclic heptapeptide with a product label. Blood-pressure increase and heart-rate decrease are labeled pharmacology, not forum color.
Melanotan, PT-141, and alpha-MSH fragments such as KPV are not the same chemical.
MC4 receptors in the hypothalamus are the sexual-function pathway for bremelanotide. MC3 and MC4 signaling also touches autonomic outflow.
The label describes transient blood-pressure rise and heart-rate drop, plus nausea. That is the biology to read next to antihypertensives, not a forum performance note.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Flush, nausea, pressure · unverified
Community reports of flushing, nausea, and pressure changes line up in direction with the bremelanotide label, then run ahead of it into unlogged combinations. Melanotan products get mixed into the same threads. They are not this molecule.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.